Drug Trial Radar · NCT03097120
The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.
Last checked: Nov 20, 2026Latest source record: May 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
309
Actual
Start
Jan 1995
Primary completion
Jan 2001
Study completion Jan 2001
Sponsor
- Lead sponsor
- Wake Forest University Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Mar 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. Methods: The investigators randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (±SD) of 3.2±0.6 years. Base-line and follow-up coronary angiograms were were analyzed by quantitative methods. Follow-up coronary angiograms were obtained after an average of 3.2 years of follow up.
Conditions
- Heart Disease
Interventions
0.625 mg of conjugated equine estrogenDrug
one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetateDrug
one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
placebo tabletsDrug
two placebo tablets daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- mean minimal coronary-artery diameterTime frame: at average of 3.2 years follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.